Smith+Nephew (NYSE: SNN) today announced plans for a months-long roadshow across Central Europe to promote its Cori surgical ...

Ladies and gentlemen, welcome to the Smith & Nephew Q1 Trading Report ... To highlight a few, CORI, EVOS, REGENETEN and our Negative Pressure Wound Therapy portfolio, all delivered strong double ...

Key platforms, such as CORI , EVOS , REGENETEN and our Negative Pressure Wound Therapy portfolio all delivered strong double-digit growth in the quarter, and we are maintaining our high ...

Smith+Nephew (NYSE ... Plan driving growth across our portfolio,” said Smith+Nephew CEO Deepak Nath. “Key platforms, such as Cori, Evos, Regeneten and our Negative Pressure Wound Therapy ...

LONDON (dpa-AFX) - Global medical technology company Smith+Nephew (SNN, SN.L), on Wednesday, reported steady revenue growth in the first quarter of 2025 despite various market challenges.

Smith & Nephew reported its first-quarter 2025 earnings, showcasing a revenue of $1.4 billion, with underlying growth at 3.1%, surpassing its guidance. The company faced a 1.2% reported growth due to ...

Smith & Nephew reported its first-quarter 2025 earnings, showcasing a revenue of $1.4 billion, with underlying growth at 3.1%, surpassing its guidance. The company faced a 1.2% reported growth due ...

(Alliance News) - Smith & Nephew PLC shares climbed on Wednesday as it said it made a good start to 2025 as revenue increased. The Watford, England-based medical technology company said first ...

"While unhelpful, recent China setbacks seem temporary and Smith+Nephew is slowly reaping the benefits from portfolio shifting toward faster-growth segments and recent R&D efforts," Jefferies analysts ...

The Smith & Nephew share price was marching higher today, topping the Footsie index in the process. Is this cheap UK stock worth considering? When investing, your capital is at risk. The value of ...

Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo’s underlying Aurix® System to the United States wound care market.